Turning Point Therapeutics (TPTX) snagged a $4.1 billion offer from Bristol Myers Squibb (BMY) on Friday, and TPTX stock more than doubled. X The deal adds repotrectinib to Bristol Myers’ wheelh...
Tag: TPTX
Turning Point Stock Doubles on Bristol Deal. What It Means for Biotech M&A.
Text size Photograph by Georges Gobet/AFP/Getty Images Turning Point Therapeutics stock has more than doubled after Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the ...